Primary efficacy and safety analysis of a global phase II study of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): The TIDAL Study
Phillips, T. Jurczak, W. Ribrag, V. Linton, Kim M Collin, G. P. Lopez-Jimenez, J. Reddy, N. Mengarelli, A. Musuraca, G. Sheehy, O.
Phillips, T.
Jurczak, W.
Ribrag, V.
Linton, Kim M
Collin, G. P.
Lopez-Jimenez, J.
Reddy, N.
Mengarelli, A.
Musuraca, G.
Sheehy, O.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Phillips T, Jurczak W, Ribrag V, Linton K, Collin GP, Lopez-Jimenez J, et al. Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study. Clinical Lymphoma Myeloma & Leukemia. 2022 Oct;22:S387-S8. PubMed PMID: WOS:000897948100434.